Abbreviations: CLC-1, cardiotrophin-like cytokine factor 1; DCD, donation after circulatory death; FSGS, focal segmental glomerulosclerosis; suPAR, soluble urokinase-type plasminogen activator receptor. that was resistant to plasmapheresis and rituximab. After exclusion of structural or immunologic damage to the kidney by repeated biopsies, the allograft was retrieved from the first recipient on day 27 and transplanted into a 52-year-old second recipient who had vascular nephropathy. Immediately after retransplantation, the allograft regained function with excellent graft function persistent now at 3 years after transplant. After 2 years on hemodialysis, the boy was listed for kidney retransplantation.
Primary focal segmental glomerulosclerosis (FSGS) recurs in up to 55% of patients after kidney transplantation. Herein we report the successful management of recurrent FSGS. A 5-year-old boy with primary FSGS received a deceased donor renal transplant. Immediate and fulminant recurrence of FSGS caused anuric graft failure that was resistant to plasmapheresis and rituximab. After exclusion of structural or immunologic damage to the kidney by repeated biopsies, the allograft was retrieved from the first recipient on day 27 and transplanted into a 52-year-old second recipient who had vascular nephropathy. Immediately after retransplantation, the allograft regained function with excellent graft function persistent now at 3 years after transplant. After 2 years on hemodialysis, the boy was listed for kidney retransplantation.
To prevent FSGS recurrence, pretreatment with ofatumumab was performed.
Nephrotic range proteinuria still occurred after the second transplantation, which responded, however, to daily plasma exchange in combination with ofatumumab. At 8 months after kidney retransplantation graft function is good. The clinical course supports the hypothesis of a circulating permeability factor in the pathogenesis of FSGS. Successful ofatumumab pretreatment implicates a key role of B cells. Herein we provide a description of successful management of kidney failure by FSGS, carefully avoiding waste of organs.
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Primary FSGS recurs in up to 55% of patients after kidney transplantation and can lead to early graft loss. The risk for recurrent FSGS is particularly high in patients with idiopathic FSGS, pediatric patients, and patients who show rapid disease progression to end-stage renal disease. Recurrence rates may exceed 80% in patients who have lost their first transplant due to disease recurrence. 1, 2 It is postulated that primary and recurrent FSGS are caused by a circulating factor affecting podocyte structure and function. This hypothesis is supported by experimental findings in isolated rat glomeruli where perfusion with patient plasma caused proteinuria. 3 Clinical observations that provide evidence for a circulating permeability factor include a report on the transmission of a permeability factor from mother to child during pregnancy, 4 recurrence of the disease within hours after transplantation from a donor without FSGS in about 30%, 2 the effect of preemptive plasmapheresis to prevent disease recurrence, 5 and the promising results of postoperative plasmapheresis to induce remission of proteinuria in recurrent FSGS. 2, 6 The postulated circulating factor has not yet been identified yet. Recent findings suggest a role for cardiotrophin-like cytokine factor 1 (CLC-1), 3 whereas the experimental findings concerning soluble urokinase-type plasminogen activator receptor (suPAR) in the pathogenesis of FSGS in humans remain conflicting. 6, 7 Here, we report on successful transplantation of a deceased donor renal allograft that failed in the first recipient due to fulminant recurrent primary FSGS and successful kidney retransplantation in the first recipient employing pretreatment with ofatumumab.
A 5-year-old boy with end-stage renal disease caused by primary FSGS (truly idiopathic FSGS) received a deceased donor renal transplant from a 31-year-old male donor with excellent renal function.
Kidney transplantation was performed through a midline incision, the renal artery and vein were anastomosed to the common iliac vessels, and the ureter was implanted into the bladder, fashioning a ureteroneocystostomy according to Lich-Grégoire. 8 Severe proteinuria Following graft loss due to FSGS recurrence, the boy was put back on dialysis for 2 years. Patients with primary FSGS carry a risk for disease recurrence of more than 80% after repeat transplantation.
2,3
Building on recent reports about the use of ofatumumab in recurrent FSGS posttransplant, 10, 11 we hypothesized that pretreatment with ofatumumab before a second kidney transplant could prevent FSGS recurrence. Ofatumumab is a human anti-CD20 monoclonal antibody that binds to a CD20 epitope different from rituximab and induces complete B-cell depletion. Greater binding avidity is thought to be responsible for improved complement-dependent cytotoxicity compared to rituximab. Due to an increase in B lymphocytes 6 months after transplantation and a concomitant rise in urinary protein levels (2.9 g/g), another infusion of ofatumumab at a dose of 1150 mg/m 2 was administered.
Ofatumumab again reduced proteinuria to subnephrotic levels All in all, this case report may extend both a novel treatment option for FSGS recurrence in kidney transplantation and a lifeboat procedure to avoid organ waste in such a high recurrence risk constellation.
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